Glycans as cancer biomarkers

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 9, 2012, Pages 1347-1353

  Adamczyk, Barbara ^a   Tharmalingam, Tharmala ^a   Rudd, Pauline M ^a  

^a NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING   (Ireland)

Author keywords

BiomarkerCancer; Glycan analysis; Glycosylation; High throughput; HPLC

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLYCAN; HAPTOGLOBIN; IMMUNOGLOBULIN G; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CARBOHYDRATE ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FUCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CANCER; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEOMICS; REVIEW; STOMACH CANCER;

ANIMALS; CARBOHYDRATE SEQUENCE; GLYCOMICS; GLYCOSYLATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; POLYSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84862840416     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2011.12.001     Document Type: Review

References (57)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics, CA, Cancer J. Clin. (2011) 20107 (caac).
2. R. Apweiler, H. Hermjakob, N. Sharon, On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database, Biochimica et Biophysica Acta (BBA) Gen. Subj. 1473 (1999) 4-8.
3. K. Ohtsubo, J.D. Marth, Glycosylation in cellular mechanisms of health and disease, Cell 126 (2006) 855-867. (Pubitemid 44310784)
4. A. Cazet, S. Julien, M. Bobowski, M.-A. Krzewinski-Recchi, A. Harduin-Lepers, S. Groux-Degroote, P. Delannoy, Consequences of the expression of sialylated antigens in breast cancer, Carbohydr. Res. 345 (2010) 1377-1383.
5. S. Rachagani, M.P. Torres, N. Moniaux, S.K. Batra, Current status of mucins in the diagnosis and therapy of cancer, Biofactors 35 (2009) 509-527.
6. D.H. Dube, C.R. Bertozzi, Glycans in cancer and inflammation [mdash] potential for therapeutics and diagnostics, Nat. Rev. Drug Discov. 4 (2005) 477-488. (Pubitemid 40861990)
7. L. Royle, M.P. Campbell, C.M. Radcliffe, D.M.White, D.J. Harvey, J.L. Abrahams, Y.-G. Kim, G.W. Henry, N.A. Shadick, M.E. Weinblatt, D.M. Lee, P.M. Rudd, R.A. Dwek, HPLC-based analysis of serumN-glycans on a 96-well plate platformwith dedicated database software, Anal. Biochem. 376 (2008) 1-12.
8. M.P. Campbell, L. Royle, C.M. Radcliffe, R.A. Dwek, P.M. Rudd, GlycoBase and autoGU: tools for HPLC-based glycan analysis, Bioinformatics 24 (2008) 1214-1216. (Pubitemid 351594175)
9. C.W. von der Lieth, A. Arda Freire, D. Blank,M.P. Campbell, A. Ceroni, D.R.Damerell, A. Dell, R.A. Dwek, B. Ernst, R. Fogh, M. Frank, H. Geyer, R. Geyer,M.J. Harrison, K. Henrick, S. Herget, W.E. Hull, J. Ionides, H.J. Joshi, J.P. Kamerling, B.R. Leeflang, T. Lutteke, M. Lundborg, K. Maass, A. Merry, R. Ranzinger, J. Rosen, L. Royle, P.M. Rudd, S. Schloissnig, R. Stenutz, W.F. Vranken, G. Widmalm, S.M. Haslam, EUROCarbDB: an open-access platform for glycoinformatics, Glycobiology 21 (2011) 493-502.
10. A. Knezevic, O. Polasek, O. Gornik, I. Rudan, H. Campbell, C. Hayward, A. Wright, I. Kolcic, N. O'Donoghue, J. Bones, P.M. Rudd, G. Lauc, Variability, heritability and environmental determinants of human plasma N-glycome, J. Proteome Res. 8 (2009) 694-701.
11. G. Lauc, A. Essafi, J.E. Huffman, C. Hayward, A. Knezevic, J.J. Kattla, O. Polasek, O. Gornik, V. Vitart, J.L. Abrahams, M. Pucic, M. Novokmet, I. Redzic, S. Campbell, S.H. Wild, F. Borovecki, W. Wang, I. Kolcic, L. Zgaga, U. Gyllensten, J.F. Wilson, A.F. Wright, N.D. Hastie, H. Campbell, P.M. Rudd, I. Rudan, Genomics meets glycomics: the first GWAS study of human N-glycome identifies HNF1A as a master regulator of plasma protein fucosylation, PLoS Genet. 6 (2010) e1001256.
12. A. Varki, Biological roles of oligosaccharides: all of the theories are correct, Glycobiology 3 (1993) 97-130. (Pubitemid 23132602)
13. B. Blomme, C. Van Steenkiste, N. Callewaert, H. Van Vlierberghe, Alteration of protein glycosylation in liver diseases, J. Hepatol. 50 (2009) 592-603.
14. D. Meany, D. Chan, Aberrant glycosylation associated with enzymes as cancer biomarkers, Clin. Proteomics 8 (2011) 7.
15. N. Callewaert, H. Van Vlierberghe, A. Van Hecke, W. Laroy, J. Delanghe, R. Contreas, Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics, Nat. Med. 10 (2004) 429-434. (Pubitemid 38508524)
16. J.A. Marrero, P.R. Romano, O. Nikolaeva, L. Steel, A. Mehta, C.J. Fimmel, M.A. Comunale, A. D'Amelio, A.S. Lok, T.M. Block, GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma, J. Hepatol. 43 (2005) 1007-1012. (Pubitemid 41627986)
17. R.l. Saffroy, P. Pham, M.m. Reffas, M. Takka, A. Lemoine, B. Debuire, New perspectives and strategy research biomarkers for hepatocellular carcinoma, Clin. Chem. Lab. Med. 45 (2007) 1169-1179. (Pubitemid 47396274)
18. G. Karvountzis, A. Redeker, Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis, Ann. Intern. Med. 80 (1974) 156-160.
19. K. Noda, E. Miyoshi, N. Uozumi, S. Yanagidani, Y. Ikeda, C.-x. Gao, K Suzuki, H Yoshihara, M Yoshikawa, K Kawano, N. Hayashi, M. Hori, N. Taniguchi, Gene expression of α1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of α-fetoprotein, Hepatology 28 (1998) 944-952. (Pubitemid 28450254)
20. Y. Sato, K. Nakata, Y. Kato, M. Shima, N. Ishii, T. Koji, K. Taketa, Y. Endo, S. Nagataki, Early recognition of hepatocellular carcinoma based on altered profiles of alphafetoprotein, N. Engl. J. Med. 328 (1993) 1802-1806. (Pubitemid 23174710)
21. N. Taniguchi, Toward cancer biomarker discovery using the glycomics approach, Proteomics 8 (2008) 3205-3208.
22. H. Friess, J. Kleeff, C. Kulli, M. Wagner, H. Sawhney, M.W. Büchler, The impact of different types of surgery in pancreatic cancer. Eur. J. Surg. Oncol. (EJSO) 25 (1999) 124.
23. M. Goggins, Molecular markers of early pancreatic cancer, J. Clin. Oncol. 23 (2005) 4524-4531. (Pubitemid 46196582)
24. D. Li, K. Xie, R. Wolff, J.L. Abbruzzese, Pancreatic cancer, Lancet 363 (2004) 1049-1057. (Pubitemid 38410779)
25. N. Okuyama, Y. Ide, M. Nakano, T. Nakagawa, K. Yamanaka, K. Moriwaki, K. Murata, H. Ohigashi, S. Yokoyama, H. Eguchi, O. Ishikawa, T. Ito, M. Kato, A. Kasahara, S. Kawano, J. Gu, N. Taniguchi, E. Miyoshi, Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation, Int. J. Cancer 118 (2006) 2803-2808. (Pubitemid 43673360)
26. E. Miyoshi, M. Nakano, Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures, Proteomics 8 (2008) 3257-3262.
27. N.H. Packer, C.-W. von der Lieth, K.F. Aoki-Kinoshita, C.B. Lebrilla, J.C. Paulson, R. Raman, P. Rudd, R. Sasisekharan, N. Taniguchi, W.S. York, Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH White Paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006), Proteomics 8 (2008) 8-20.
28. A. Heidenreich, G. Aus, M. Bolla, S. Joniau, V.B. Matveev, H.P. Schmid, F. Zattoni, EAU guidelines on prostate cancer, Eur. Urol. 53 (2008) 68-80. (Pubitemid 350166735)
29. W.J. Catalona, D.S. Smith, T.L. Ratliff, K.M. Dodds, D.E. Coplen, J.J.J. Yuan, J.A. Petros, G.L. Andriole, Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, N. Engl. J. Med. 324 (1991) 1156-1161.
30. M.V. Dwek, A. Jenks, A.J.C. Leathem, A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia, Clin. Chim. Acta 411 (2010) 1935-1939.
31. H. Lilja, D. Ulmert, A.J. Vickers, Prostate-specific antigen and prostate cancer: prediction, detection and monitoring, Nat. Rev. Cancer 8 (2008) 268-278. (Pubitemid 351430866)
32. R. Saldova, Y. Fan, J.M. Fitzpatrick, R.W.G. Watson, P.M. Rudd, Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia, Glycobiology 21 (2011) 195-205.
33. R. Peracaula, S. Barrabes, A. Sarrats, P.M. Rudd, R. de Llorens, Altered glycosylation in tumours focused to cancer diagnosis, Dis. Markers 25 (2008) 207-218.
34. Z. Kyselova, Y. Mechref, M.M. Al Bataineh, L.E. Dobrolecki, R.J. Hickey, J. Vinson, C.J. Sweeney, M.V. Novotny, Alterations in the serum glycome due to metastatic prostate cancer, J. Proteome Res. 6 (2007) 1822-1832. (Pubitemid 46814506)
35. A. Sarrats, R. Saldova, J. Comet, N. O'Donoghue, R. de Llorens, P.M. Rudd, R. Peracaula, Glycan characterization of PSA 2-DE subforms from serum and seminal plasma, OMICS: A J. of Integr. Biol. 14 (2010) 465-474.
36. A. Sarrats, J. Comet, G. Tabares, M. Ramirez, R.N. Aleixandre, R. de Llorens, R. Peracaula, Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis, Prostate 70 (2010) 1-9.
37. M.J. Duffy, J.M. Bonfrer, J. Kulpa, G.J. Rustin, G. Soletormos, G.C. Torre, M.K. Tuxen, M. Zwirner, CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use, Int. J. Gynecol. Cancer 15 (2005) 679-691. (Pubitemid 41783071)
38. R.C.J. Bast, D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K.A. Baggerly, E.N. Atkinson, S. Skates, Z. Zhang, New tumor markers: CA125 and beyond, Int. J. Gynecol. Cancer 15 (2005) 274-281. (Pubitemid 43096594)
39. R. Saldova, L. Royle, C.M. Radcliffe, U.M. Abd Hamid, R. Evans, J.N. Arnold, R.E. Banks, R. Hutson, D.J. Harvey, R. Antrobus, Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG, Glycobiology 17 (2007) 1344.
40. U.M. Abd Hamid, L. Royle, R. Saldova, C.M. Radcliffe, D.J. Harvey, S.J. Storr, M. Pardo, R. Antrobus, C.J. Chapman, N. Zitzmann, A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression, Glycobiology 18 (2008) 1105.
41. Z. Kyselova, Y. Mechref, P. Kang, J.A. Goetz, L.E. Dobrolecki, G.W. Sledge, L. Schnaper, R.J. Hickey, L.H. Malkas, M.V. Novotny, Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles, Clin. Chem. 54 (2008) 1166-1175. (Pubitemid 352009693)
42. A. Pierce, R. Saldova, U.M. Abd Hamid, J.L. Abrahams, E.W. McDermott, D. Evoy, M.J. Duffy, P.M. Rudd, Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients, Glycobiology 20 (2010) 1283.
43. R. Saldova, J. Reuben, U. Abd Hamid, P. Rudd, M. Cristofanilli, Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts, Ann. Oncol. 22 (2011) 1113-1119.
44. J.A. Bonner, J.A. Sloan, K.M. Rowland, G.G. Klee, J.W. Kugler, J.A. Mailliard, M. Wiesenfeld, J.E. Krook, A.W. Maksymiuk, E.G. Shaw, R.S. Marks, E.A. Perez, Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer, Clin. Cancer Res. 6 (2000) 597-601. (Pubitemid 30111484)
45. H.-J. Sung, J.-Y. Cho, Biomarkers for the lung cancer diagnosis and their advances in proteomics, BMB Rep. 41 (2008) 615-625.
46. J. Schneider, Tumor markers in detection of lung cancer, Adv. Clin. Chem. 42 (2006) 1-41. (Pubitemid 44302105)
47. R. Molina, X. Filella, J.M. Augé, ProGRP: a new biomarker for small cell lung cancer, Clin. Biochem. 37 (2004) 505-511. (Pubitemid 38845013)
48. J.N. Arnold, R. Saldova, M.C. Galligan, T.B. Murphy, Y. Mimura-Kimura, J.E. Telford, A.K. Godwin, P.M. Rudd, Novel glycan biomarkers for the detection of lung cancer, J. Proteome Res. 10 (2011) 1755-1764.
49. W. You, L. Zhang, M.H. Gail, Y. Chang, W. Liu, J. Ma, J. Li, M. Jin, Y. Hu, C. Yang, Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors, J. Natil. Cancer Inst. 92 (2000) 1607.
50. Y. Saikawa, K. Fukuda, T. Takahashi, R. Nakamura, H. Takeuchi, Y. Kitagawa, Gastric carcinogenesis and the cancer stem cell hypothesis, Gastric Cancer 13 (2010) 11-24.
51. M. Carpelan-Holmstrom, J. Louhimo, U. Stenman, H. Alffhan, C. Haglund, CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers, Anticancer. Res. 22 (2002) 2311-2316. (Pubitemid 34857058)
52. J. Bones, J.C. Byrne, N. O'Donoghue, C. McManus, C. Scaife, H. Boissin, A. Nastase, P.M. Rudd, Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defence response mechanisms, J. Proteome Res. 10 (2011) 1246-1265.
53. J. Bones, S. Mittermayr, N. O'Donoghue, A. Guttman, P.M. Rudd, Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation, Anal. Chem. 82 (2010) 10208-10215.
54. K. Mariño, J. Bones, J.J. Kattla, P.M. Rudd, A systematic approach to protein glycosylation analysis: a path through the maze, Nat. Chem. Biol. 6 (2010) 713-723.
55. G.R. Guile, P.M. Rudd, D.R. Wing, S.B. Prime, R.A. Dwek, A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles, Anal. Biochem. 240 (1996) 210-226. (Pubitemid 26304265)
56. J. Ahn, J. Bones, Y.Q. Yu, P.M. Rudd, M. Gilar, Separation of 2-aminobenzamide labeled glycans using hydrophilic interaction chromatography columns packed with 1.7 um sorbent, J. Chromatogr. B 878 (2010) 403-408.
57. M. Pucic, A. Knezevic, J. Vidic, B. Adamczyk, M. Novokmet, O. Polasek, O. Gornik, S. Supraha-Goreta, M.R. Wormald, I. Redzic, H. Campbell, A. Wright, N.D. Hastie, J.F. Wilson, I. Rudan, M. Wuhrer, P.M. Rudd, D. Josic, G. Lauc, High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations, Mol. Cell Proteomics (2011) 10.